Immunogenicity of Fractional Dose Inactivated Poliovirus Vaccine in India.
EPI schedule
India
fractional dose inactivated poliovirus vaccine
immunogenicity
Journal
Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049
Informations de publication
Date de publication:
23 Feb 2022
23 Feb 2022
Historique:
received:
11
03
2021
accepted:
17
09
2021
pubmed:
19
11
2021
medline:
26
2
2022
entrez:
18
11
2021
Statut:
ppublish
Résumé
Following the withdrawal of Sabin type 2 from trivalent oral poliovirus vaccine (tOPV) in 2016, the introduction of ≥1 dose of inactivated poliovirus vaccine (IPV) in routine immunization was recommended, either as 1 full dose (0.5mL, intramuscular) or 2 fractional doses of IPV (fIPV-0.1mL, intradermal). India opted for fIPV. We conducted a comparative assessment of IPV and fIPV. This was a 4-arm, open-label, multicenter, randomized controlled trial. Infants were enrolled and vaccines administered according to the study design, and the blood was drawn at age 6, 14, and 18 weeks for neutralization testing against all 3 poliovirus types. Study enrolled 799 infants. The seroconversion against type 2 poliovirus with 2 fIPV doses was 85.8% (95% confidence interval [CI]: 80.1%-90.0%) when administered at age 6 and 14 weeks, 77.0% (95% CI: 70.5-82.5) when given at age 10 and 14 weeks, compared to 67.9% (95% CI: 60.4-74.6) following 1 full-dose IPV at age 14 weeks. The study demonstrated the superiority of 2 fIPV doses over 1 full-dose IPV in India. Doses of fIPV given at 6 and 14 weeks were more immunogenic than those given at 10 and 14 weeks. Clinical Trial Registry of India (CTRI). Clinical trial registration number was CTRI/2017/02/007793.
Identifiants
pubmed: 34791350
pii: 6430128
doi: 10.1093/jpids/piab091
pmc: PMC8865014
doi:
Substances chimiques
Antibodies, Viral
0
Poliovirus Vaccine, Inactivated
0
Poliovirus Vaccine, Oral
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
60-68Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : WHO, Geneva
ID : 65163
Organisme : World Health Organization
ID : 65163
Pays : International
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society.
Références
Bull World Health Organ. 1996;74(3):253-68
pubmed: 8789924
Lancet. 2019 Jun 29;393(10191):2624-2634
pubmed: 31104832
Methods Mol Biol. 2016;1387:145-76
pubmed: 26983734
Lancet Infect Dis. 2012 Feb;12(2):128-35
pubmed: 22071249
Vaccine. 2015 Sep 8;33(37):4719-26
pubmed: 25862299
MMWR Morb Mortal Wkly Rep. 2018 Oct 26;67(42):1189-1194
pubmed: 30359342
J Infect Dis. 2007 Jan 1;195(1):12-20
pubmed: 17152004
J Infect Dis. 2018 Jan 17;217(3):443-450
pubmed: 29126173
J Infect Dis. 2017 Jul 1;216(suppl_1):S161-S167
pubmed: 28838185
J Infect Dis. 2014 Nov 1;210 Suppl 1:S439-46
pubmed: 24634499
Clin Infect Dis. 2018 Oct 30;67(suppl_1):S57-S65
pubmed: 30376095
Vaccine. 2017 May 31;35(24):3209-3214
pubmed: 28479178
MMWR Morb Mortal Wkly Rep. 2019 Jul 26;68(29):642-646
pubmed: 31344023
Lancet. 2015 Dec 12;386(10011):2413-21
pubmed: 26388534
Vaccine. 2015 Jan 3;33(2):307-13
pubmed: 25448109